received research support from Cerenovus Inc, Medtronic, Endovascular Engineering, Frontier Bio, Sensome Inc, Endomimetics, Ancure LLC, Neurogami Medical, MIVI Biosciences, Monarch Biosciences, Stryker, Conway Medical, Piraeus Medical, Rion Inc, and Bionaut Labs
Dose may be increased to 7.2 mg subcutaneously once weekly on patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated
Divide the dose you want by the concentration printed on your vial, then multiply by 100 to convert milliliters to syringe units
Raju et al., 2018
This gradual increase helps mitigate potential gastrointestinal side effects often associated with GLP-1 receptor agonists
If your nausea is severe or lasts a long time, try not to drink during meals and for 30 to 60 minutes before and after eating